High population immunity from prior SARS-CoV-2 infections and vaccinations, combined with low-severity circulation of Omicron sublineages such as XFG, NB.1.8.1, and BA.3.2, underpins the 96% market-implied probability against a new coronavirus pandemic in 2026. Official CDC and WHO surveillance shows very low emergency department visits (0.3%) and stable or modestly elevated Rt values around 1.08, with no variants meeting criteria for increased virulence or pandemic potential. Historical analogs and current genomic monitoring indicate that incremental mutations confer transmissibility advantages without triggering widespread severe disease or overwhelming healthcare systems. Realistic scenarios that could shift outcomes include emergence of a novel zoonotic coronavirus or a major antigenic shift enabling immune escape with higher pathogenicity, though ongoing wastewater and genomic surveillance would likely detect such developments early.